Article

The V617F mutation in JAK2 renders myeloid cells more sensitive to IL-6-mediated gp130 signaling

2025-10-10

Abstract excerpt

The somatic V617F mutation in the pseudokinase domain of JAK2 (JAK2VF) causes various phenotypes of myeloproliferative neoplasms (MPN). By interacting with cytokine receptors such as those for erythropoietin (EPO) or thrombopoietin (TPO), JAK2VF induces ligand-independent dimerization and activation, leading to deregulated blood cell production, cytokine hypersensitivity, and inflammatory cytokine release. Interle...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2f0c775d-3cea-5708-a4a3-ea22c0245e47
DOI: 10.1101/2025.10.10.681590

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The V617F mutation in JAK2 renders myeloid cells more sensitive to IL-6-mediated gp130 signalingDOI 10.1101/2025.10.10.681590Read

Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative NeoplasmsSemantic proximity Read

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative DisordersSemantic proximity Read

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read

Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.Semantic proximity Read

Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.Semantic proximity Read

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read

The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.Semantic proximity Read

Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.Semantic proximity Read

Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.Semantic proximity Read

Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven activation from cytokine-induced stimulation.Semantic proximity Read

JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors.Semantic proximity Read

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.Semantic proximity Read